{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:13:23Z","timestamp":1789402403595,"version":"build-2803163510"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The treatment of residual\/recurrent cervical cancer within a previously irradiated area is challenging and generally associated with a poor outcome. Local treatments such as salvage surgery and re-irradiation are usually traumatic and have limited efficacy. High intensity focused ultrasound (HIFU) treatment can directly ablate solid tumors without damaging neighboring healthy tissue. However, the HIFU studies for these patients are limited. Experience gained over the course of 10 years with the use of HIFU for the management of residual\/recurrent cervical cancer after chemoradiotherapy is reported herein.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>153 patients with residual\/recurrent cervical cancer in a previously irradiated field who received HIFU treatment between 2010 and 2021 were retrospectively analyzed. Adverse effects, survival benefit and factors affecting prognosis were given particular attention.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 36 patients (23.5%) achieved a partial response following HIFU treatment and 107 patients (69.9%) had stable disease. The objective response and disease control rates were 23.5% and 93.5%, respectively. The median progression-free survival (mPFS) and median overall survival (mOS) were 17.0 months and 24.5 months, respectively. Moreover, patients with lesions \u22651.40 cm before HIFU treatment and a shrinkage rate \u2265 30% after treatment had a higher mPFS and mOS, and patients with lesions \u22641.00 cm after HIFU treatment had a higher mPFS (P=&amp;lt;0.05). All the treatment-related adverse events were limited to minor complications, which included skin burns, abdominal pain and vaginal discharge.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>HIFU treatment is likely a preferred option for cervical cancer patients with residual disease or recurrence following CRT that can safely improve the local control rate and extend survival.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.995930","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T06:50:50Z","timestamp":1665989450000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Salvage high intensity focused ultrasound for residual or recurrent cervical cancer after definitive chemoradiotherapy"],"prefix":"10.3389","volume":"13","author":[{"given":"Qin","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuncong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokai","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shisheng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"key":"B1","volume-title":"World cancer report: cancer research for cancer prevention","author":"Wild","year":"2020"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.6.500a","article-title":"New standard of care for cervical cancer sets stage for next questions","volume":"91","author":"McNeil","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.05.043","article-title":"Total laparoscopic radical hysterectomy for locally advanced cervical carcinoma (stages IIB, IIA and bulky stages IB) after concurrent chemoradiation therapy: surgical morbidity and oncological results","volume":"114","author":"Colombo","year":"2009","journal-title":"Gynecol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.08.004","article-title":"Long-term analysis of clinical outcome and complications in locally advanced cervical cancer patients administered concomitant chemoradiation followed by radical surgery","volume":"119","author":"Ferrandina","year":"2010","journal-title":"Gynecol Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx220","article-title":"Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Marth","year":"2017","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/igc.0000000000000171","article-title":"Radical surgery in patients with residual disease after (chemo)radiation for cervical cancer","volume":"24","author":"Boers","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.09.006","article-title":"Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a gynecologic oncology group study","volume":"116","author":"Moore","year":"2010","journal-title":"Gynecol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2010.11.016","article-title":"Completion surgery or not after concurrent chemoradiotherapy for locally advanced cervical cancer","volume":"155","author":"L\u00e8guevaque","year":"2011","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B9","article-title":"The role of completion surgery after concurrent radiochemotherapy in locally advanced stages IB2-IIB cervical cancer","volume":"33","author":"Chereau","year":"2013","journal-title":"Anticancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/gco.0000000000000042","article-title":"Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer","volume":"26","author":"Eskander","year":"2014","journal-title":"Curr Opin Obstet Gynecol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1186\/s12885-020-07672-w","article-title":"Propensity score-matched analysis of systemic chemotherapy versus salvage hysterectomy for persistent cervical cancer after definitive radiotherapy\/concurrent chemoradiotherapy","volume":"20","author":"Takekuma","year":"2020","journal-title":"BMC Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic oncology group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2011.02.011","article-title":"Multimodality approach in extra cervical locally advanced cervical cancer: chemoradiation, surgery and intra-operative radiation therapy. a phase II trial","volume":"37","author":"Giorda","year":"2011","journal-title":"Eur J Surg Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2013.10.006","article-title":"Evaluation and impact of residual disease in locally advanced cervical cancer after concurrent chemoradiation therapy: results of a multicenter study","volume":"39","author":"Hequet","year":"2013","journal-title":"Eur J Surg Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.12026","article-title":"Hysterectomy for Recurrent\/Residual cervical cancer following definitive radiotherapy","volume":"34","author":"Nakasone","year":"2020","journal-title":"In Vivo"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13421","article-title":"Should we cease to perform salvage hysterectomy after chemoradiation and brachytherapy in locally advanced cervical cancer","volume":"39","author":"Gosset","year":"2019","journal-title":"Anticancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.14093","article-title":"Salvage surgery for patients with residual disease after chemoradiation therapy for locally advanced cervical cancer: A systematic review on indication, complications, and survival","volume":"100","author":"van Kol","year":"2021","journal-title":"Acta Obstet Gynecol Scand"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604619","article-title":"Adjuvant hysterectomy for treatment of residual disease in patients with cervical cancer treated with radiation therapy","volume":"99","author":"Ota","year":"2008","journal-title":"Br J Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1259\/bjr\/17150274","article-title":"High intensity focused ultrasound: surgery of the future","volume":"76","author":"Kennedy","year":"2003","journal-title":"Br J Radiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20130044","article-title":"High-intensity focused ultrasound: advances in technology and experimental trials support enhanced utility of focused ultrasound surgery in oncology","volume":"86","author":"Malietzis","year":"2013","journal-title":"Br J Radiol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s10439-021-02833-9","article-title":"High-intensity focused ultrasound: A review of mechanisms and clinical applications","volume":"49","author":"Bachu","year":"2021","journal-title":"Ann BioMed Eng"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2011.01.047","article-title":"Treatment with high intensity focused ultrasound: secrets revealed","volume":"81","author":"Shehata","year":"2012","journal-title":"Eur J Radiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40349-015-0043-6","article-title":"Ultrasound-guided trans-rectal high-intensity focused ultrasound (HIFU) for advanced cervical cancer ablation is feasible: a case report","volume":"3","author":"Abel","year":"2015","journal-title":"J Ther Ultrasound"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2021.1889698","article-title":"High-intensity focused ultrasound ablation in the treatment of recurrent ovary cancer and metastatic pelvic tumors: a feasibility study","volume":"38","author":"Lei","year":"2021","journal-title":"Int J Hyperthermia"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-update and clarification: From the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/01.rvi.0000094584.83406.3e","article-title":"Society of interventional radiology clinical practice guidelines","volume":"14","author":"Sacks","year":"2003","journal-title":"J Vasc Interv Radiol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1080\/02656736.2021.1895330","article-title":"Targetability of cervical cancer by magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU)-mediated hyperthermia (HT) for patients receiving radiation therapy","volume":"38","author":"Zhu","year":"2021","journal-title":"Int J Hyperthermia"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ultsonch.2004.01.011","article-title":"Extracorporeal high intensity focused ultrasound ablation in the treatment of 1038 patients with solid carcinomas in China: an overview","volume":"11","author":"Wu","year":"2004","journal-title":"Ultrason Sonochem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.09.039","article-title":"Focal high intensity focused ultrasound of unilateral localized prostate cancer: A prospective multicentric hemiablation study of 111 patients","volume":"71","author":"Rischmann","year":"2017","journal-title":"Eur Urol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/s0360-3016(03)00288-8","article-title":"Combination external beam radiotherapy and high-dose-rate intracavitary brachytherapy for uterine cervical cancer: analysis of dose and fractionation schedule","volume":"56","author":"Toita","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.radonc.2005.11.014","article-title":"Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology","volume":"78","author":"P\u00f6tter","year":"2006","journal-title":"Radiother Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1259\/bjr\/30377872","article-title":"Dose escalation in brachytherapy for cervical cancer: impact on (or increased need for) MRI-guided plan optimisation","volume":"85","author":"Paton","year":"2012","journal-title":"Br J Radiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.618485","article-title":"Selection of treatment regimens for recurrent cervical cancer","volume":"11","author":"Chao","year":"2021","journal-title":"Front Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2019.30.e9","article-title":"Efficacy and dosimetry analysis of image-guided radioactive 125I seed implantation as salvage treatment for pelvic recurrent cervical cancer after external beam radiotherapy","volume":"30","author":"Qu","year":"2019","journal-title":"J Gynecol Oncol"},{"key":"B37","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-12468-6","volume-title":"Re-irradiation: new frontiers. re-irradiation: New frontiers","author":"Nieder","year":"2011"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.08.042","article-title":"The impact of age in the outcome of patients with advanced or recurrent cervical cancer after platinum-based chemotherapy","volume":"104","author":"Kastritis","year":"2007","journal-title":"Gynecol Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.11652","article-title":"Local radiotherapy or chemotherapy for oligo-recurrent cervical cancer in patients with prior pelvic irradiation","volume":"33","author":"Kobayashi","year":"2019","journal-title":"In Vivo"},{"key":"B40","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/jrr\/rrs092","article-title":"Permanent interstitial re-irradiation with au-198 seeds in patients with post-radiation locally recurrent uterine carcinoma","volume":"54","author":"Okazawa","year":"2013","journal-title":"J Radiat Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.995930\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T06:50:55Z","timestamp":1665989455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.995930\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,17]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2022.995930"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.995930","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,17]]},"article-number":"995930"}}